Overview

Tiotropium Bromide Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease

Status:
Completed
Trial end date:
2021-04-26
Target enrollment:
Participant gender:
Summary
A Phase 2, Randomized, Partially-blinded, Parallel Group, Dose-ranging Study to Assess the Pharmacodynamics, Relative Bioavailability, and Safety of Three Doses of Tiotropium Bromide Inhalation Solution in Subjects with Chronic Obstructive Pulmonary Disease
Phase:
Phase 2
Details
Lead Sponsor:
Nephron Pharmaceuticals Corporation
Collaborator:
Rho, Inc.
Treatments:
Bromides
Tiotropium Bromide